Clinical Trial Update: Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation trial evaluating the combination of everolimus and dovitinib in metastatic clear cell renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Dovitinib (dovitinib)
• Everolimus (everolimus)

Snippet

Sponsor: Queen Mary University of London | Conditions: Metastatic Clear Cell Renal Cancer | Phase 1 | Status: COMPLETED